Brammer bio

Brammer Bio is a leading Contract Development and Manufacturing Organization (CDMO) that specializes in viral vector manufacturing. The company is a subsidiary of Thermo Fisher Scientific, one of the world's largest life sciences companies. Brammer Bio offers an integrated viral vector manufacturing solution that includes process development, clinical and commercial manufacturing, and analytical services.

With its global network of facilities in the United States and Europe, Brammer Bio has become the world's largest viral vector CDMO. The company has extensive experience in developing and producing viral vectors for gene therapy applications, including adeno-associated virus (AAV), lentivirus, adenovirus, and retrovirus vectors.

Brammer Bio's state-of-the-art facilities are equipped with cutting-edge technologies to ensure high-quality production of viral vectors. The company's team of experts includes scientists with decades of experience in bioprocessing, cell culture development, purification processes, analytical methods development/validation/transfer.

The company offers end-to-end solutions for clients looking to develop gene therapies or other advanced therapeutics using viral vectors. Brammer Bio can support clients from early-stage process development through clinical trials to commercialization.

One key advantage that sets Brammer Bio apart from other CDMOs is its ability to provide fully integrated services under one roof. This means that clients can work with a single partner throughout their entire product lifecycle rather than having to switch between multiple vendors at different stages.

Brammer Bio also places a strong emphasis on quality control throughout its operations. The company adheres to strict regulatory guidelines set by agencies such as the FDA and EMA (European Medicines Agency) to ensure compliance with current Good Manufacturing Practices (cGMP).

In addition to its core capabilities in viral vector manufacturing for gene therapy applications, Brammer Bio also offers expertise in other areas such as plasmid DNA production and cell line engineering services.

Overall, Brammer Bio is an industry leader when it comes to providing comprehensive solutions for advanced therapeutics using viral vectors. With its global network of facilities staffed by experienced scientists and engineers who are committed to quality control at every step along the way – from process development through commercialization – this CDMO is well-positioned for continued growth as demand for gene therapies continues to rise around the world.